Related Experiment Video
Updated: Jan 27, 2026

Recovery of Adult Zebrafish Hearts for High-throughput Applications
Published on: December 12, 2014
External applicability of the COMPASS trial: the Western Denmark Heart Registry
Morten Würtz1,2, Kevin Kris Warnakula Olesen1,3, Troels Thim1
1Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK Aarhus, Denmark.
Insights
In a study of patients undergoing coronary angiography, only 15% met criteria for combined aspirin and rivaroxaban treatment. These eligible patients experienced significantly higher cardiovascular event rates, indicating an unmet need for better prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Epidemiology
Background:
- The COMPASS trial demonstrated benefits of combined aspirin and rivaroxaban for ischemic events in stable coronary artery disease (CAD) or peripheral artery disease (PAD).
- Determining the proportion of patients eligible for this treatment in real-world settings is crucial for understanding its potential impact.
Purpose of the Study:
- To estimate the prevalence of COMPASS-eligible patients among unselected individuals undergoing coronary angiography (CAG).
- To compare cardiovascular event rates between COMPASS-eligible and non-eligible patients with CAD/PAD.
Main Methods:
- A cohort of 80,071 patients undergoing CAG in Western Denmark (2004-2011) was analyzed.
- COMPASS eligibility criteria were applied to identify patients with CAD/PAD who met inclusion criteria.
- Primary endpoint (cardiovascular death, ischemic stroke, hemorrhagic stroke, myocardial infarction) rates were compared using adjusted incidence rate ratios (aIRRs).
Main Results:
- Of 52,132 patients with CAD/PAD, 11,930 (approximately 23%) were COMPASS eligible.
- COMPASS eligible patients had a 1.7-fold higher rate of the primary endpoint compared to non-eligible patients.
- Higher risks were observed for cardiovascular death (aIRR 2.5), ischemic stroke (aIRR 1.4), and myocardial infarction (aIRR 1.9) in eligible patients.
Conclusions:
- Only 15% of the studied 'all-comers' CAG cohort were eligible for the COMPASS treatment regimen.
- COMPASS-eligible patients exhibited substantially higher rates of cardiovascular events, up to 2.5 times greater than non-eligible counterparts.
- These findings underscore an unmet need for enhanced preventive strategies in high-risk cardiovascular patients.
Aims:
In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). We estimated the proportion of COMPASS eligible patients among unselected patients undergoing coronary angiography (CAG) and compared outcome rates among COMPASS eligible and non-eligible patients.
Methods And Results:
We applied the COMPASS study criteria on patients undergoing CAG in Western Denmark (2004-11). Both COMPASS eligible and non-eligible patients had CAD/PAD and met no exclusion criteria, but only COMPASS eligible patients met the inclusion criteria. We assessed the COMPASS primary endpoint of cardiovascular death, ischaemic stroke, haemorrhagic stroke, or myocardial infarction (MI). We computed event rates and adjusted incidence rate ratios (aIRRs). Of 80 071 patients undergoing CAG, 27 939 did not have CAD or PAD and were not considered. Of the 52 132 patients remaining, 11 930 were COMPASS eligible. Rates of the primary endpoint were 4.8 (95% confidence interval 4.6-5.0) events per 100 person-years among COMPASS eligible patients and 2.3 (2.2-2.4) among COMPASS non-eligible patients [aIRR 1.7 (1.6-1.9)]. COMPASS eligible patients also had higher risks of cardiovascular death [aIRR 2.5 (2.1-3.0)], ischaemic stroke [aIRR 1.4 (1.2-1.6)], and MI [aIRR 1.9 (1.7-2.1)].
Conclusion:
In this all-comers CAG cohort, 15% were eligible for combined aspirin and rivaroxaban treatment. COMPASS eligible patients had up to 2.5-fold higher rates of cardiovascular events than non-eligible patients. The higher incidence of ischaemic events in COMPASS eligible patients highlights an unmet need for additional preventive measures.
Related Concept Videos
Compass
Western Blotting
The technique begins with separating proteins from the sample using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by protein transfer, immunoblotting, and finally, protein detection.
Design Example: Marking Boundaries of a Site Using a Compass
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm

